Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses
about
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrationsAzithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosisPharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis.Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis.Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan.Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilmsIntrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjectsTransplacental transfer of Azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model.Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniaeBlood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells.Budesonide, fluticasone propionate, and azithromycin do not modulate the membrane vesicle release by THP-1 macrophages and respiratory pathogens during macrophage infection.Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjectsEffect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.
P2860
Q30662421-072004A1-8AFD-49D8-9AD8-9D3EFA40961CQ33317067-B9DAE203-B0AA-49E4-9937-3BEA26627DD1Q33640512-1C8636F5-F0C1-4A41-BCE2-CB6F55BB1CD7Q33975933-7D4864E1-6898-43CB-BAA7-232CD5DB72D1Q34228376-829FF3E5-F51E-4875-946B-BB4A73617C9BQ35136913-EFBF8F6B-4C12-41F4-A324-2C6846AFC0F0Q35166134-DB1A492F-468C-42DE-9D43-B6DCD4417EA9Q35589481-8996E064-8879-4D47-82E3-833D58469540Q35784460-06EAAFD8-97FD-41A1-9C64-F89BA4B46938Q35941279-A936A745-F2C6-4069-BB8E-3B5A523C58C5Q36422690-201EB734-136E-4ED0-A433-30EF9170C492Q36422696-69702A7F-403A-4298-8257-B480F76C5808Q36936597-CEC2230F-2810-47F0-A76D-9B03C63260A1Q36969875-7E928EBD-1D15-4C55-BDDC-9467AA70E69EQ37604462-528218C9-D755-4675-818C-566372C5B1A1Q39470774-2C4C4614-EE15-4BDD-BFCA-9E1D0BBD8040Q39766949-D973B6DD-E0D0-40A0-8ADA-1550629599FEQ39955901-DB49A3AC-10EB-406B-BA11-9EBAB673771AQ40204809-A830B14E-4CE7-4F1F-B82B-6FA388A48D69Q41969496-64BC6C7C-7CFE-4DBD-BB57-708BC8A70327Q42111448-A0C96918-2FD8-4292-BAB3-555098277506Q43181838-8E940362-2E43-4984-9161-68544DD74CB6
P2860
Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
Intrapulmonary pharmacokinetic ...... lunteers given five oral doses
@ast
Intrapulmonary pharmacokinetic ...... lunteers given five oral doses
@en
type
label
Intrapulmonary pharmacokinetic ...... lunteers given five oral doses
@ast
Intrapulmonary pharmacokinetic ...... lunteers given five oral doses
@en
prefLabel
Intrapulmonary pharmacokinetic ...... lunteers given five oral doses
@ast
Intrapulmonary pharmacokinetic ...... lunteers given five oral doses
@en
P2093
P2860
P1476
Intrapulmonary pharmacokinetic ...... lunteers given five oral doses
@en
P2093
Campbell GD Jr
Gubbins PO
Halinski DM
San Pedro G
P2860
P304
P407
P577
1996-11-01T00:00:00Z